ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
Chronic graft-versus-host disease: where do we go from here?
Author(s): Farag S
Source: BONE MARROW TRANSPLANTATION    Volume: 33    Issue: 6    Pages: 569-577    Published: MAR 2004  
Times Cited: 28     References: 78     
Abstract: Chronic graft-versus-host disease (GvHD) remains a significant cause of late morbidity and mortality following allogeneic stem cell transplantation. However, patients with chronic GvHD are very heterogeneous, making evaluation and treatment difficult. Corticosteroids remain the most effective primary treatment of this condition. Randomized trials have not confirmed the beneficial effect of additional cyclosporine, even in patients with higher risk features. For patients failing initial therapy, no standard therapy is available. A plethora of drugs have been reported to have activity and promise in this disease. However, the majority of reports are small retrospective studies, with few prospective trials. The marked variability in the reported response rates for many of these novel agents highlights a number of problems in the evaluation and management of chronic GvHD. In addition to the heterogeneity of patients, there are no uniform definitions for treatment failure, prognostic criteria to stratify patients according to risk, or to evaluate response to treatment, which in many cases is largely subjective. The challenge ahead is to develop more uniform criteria for de. ning many of these important variables, which is likely to lead to the design of better prospective clinical trials to improve the outcome of patients with this condition.
Document Type: Review
Language: English
Reprint Address: Farag, S (reprint author), Ohio State Univ, Div Hematol & Oncol, Ctr Comprehens Canc, Bone Marrow Transplant Program, A433A Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA
Addresses:
1. Ohio State Univ, Div Hematol & Oncol, Ctr Comprehens Canc, Bone Marrow Transplant Program, Columbus, OH 43210 USA
Publisher: NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
Subject Category: Biophysics; Oncology; Hematology; Immunology; Transplantation
IDS Number: 801FA
ISSN: 0268-3369
DOI: 10.1038/sj.bmt.1704410
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo